Povezanost nivoa adiponektina u serumu pacijenata u zavisnosti od metaboličkog sindroma i koronarne bolesti
Author
Stojanović, SanjaMentor
Đukić, Aleksandar
Committee members
Živančević-Simonović, Snežana
Dimić, Aleksandar
Pejnović, Nada
Deljanin Ilić, Marina

Metadata
Show full item recordAbstract
Dosadašnje studije potvrđuju da adiponektin, protein koji luče
adipociti, ostvaruje kardiovaskuloprotektivnu, antiaterogenu, anti-
inflamatornu, antiadhezivnu, vazodilatatornu, antikataboličku i
antidijabetičnu ulogu. Hipoadiponektinemija doprinosi patofiziologiji
metaboličkog sindroma i koronarne bolesti, čak može biti nezavistan
kardiovaskularni faktor rizika. Nivo adiponektina u serumu može biti
rani marker ovih entiteta, metaboličkog sindroma i koronarne bolesti.
Metod: Kliničko-laboratorijska studija preseka obuhvatila je 100
ispitanika oba pola sa metaboličkim sindromom i koronarnom bolešću.
Korišćene su sledeće metode: klinički pregled, antropometrijska merenja,
određivanje ukupne količne masnog tkiva osteodenzitometrijom, labora-
torijska ispitivanja [koncentracija adiponektina u serumu ELISA metodom,
insulina RIA metodom, glikemija OGTT-om, lipidni parametri (HOL,
HDL, LDL, trigliceridi) i C-reaktivni protein], elektrokardiogramsko,
ehokardiografsko merenje, anal...iza koronarografskih nalaza i izračunavanje
aterogenih i HOMA-indeksa.
Rezultati: Nivo adiponektina je u negativnoj korelaciji sa parametrima
metaboličkog sindroma (gojaznost, hipertenzija, hiperglikemija i insulinska
rezistencija, dislipidemija) i koronarne bolesti (broj suženja koronarnih
arterija i progresija bolesti) i u pozitivnoj korelaciji sa ejekcijonom
frakcijom, dijastolnom funkcijom i HDL-holesterolom. Adiponektin može
biti značajan prediktor metaboličkog sindroma i koronarne bolesti i rani
reprezentativni marker miokardne ishemije i vaskularne inflamacije,
a hipoadiponektinemija nezavistan kardiovaskularni faktor rizika.
Zaključak: Studija, prva te vrste u Srbiji, a jedna od retkih u svetu, daće
značajan doprinos izučavanju adiponektina kao ranog reprezentativnog,
dijagnostičkog i prediktivnog markera kod bolesnika sa metaboličkim
sindromom i koronarnom bolešću.
Up to date studies are confirming that adiponectin, a cytokine
produced by adipocytes, exerts cardiovascular-protective role including antiatherogenic,
anti-inflammatory, anti-adherent, vasodilator, anticatabolic and antidiabetic
effects. Hypoadiponectinaemia contributes to the pathophysiology of
the metabolic syndrome and coronary artery disease. The level of adiponectin
in serum may be seen as an independent cardiovascular risk factor. In addition,
the level of circulating adiponectin may be an early marker of the conditions such
as metabolic syndrome and coronary artery disease.
Methods: This research represents the clinical-laboratory cross-sectional study,
based on the cases of 100 patients of both sexes with metabolic syndrome and/or
coronary artery disease. Following methods were used: a clinical examination,
anthropometric measurements, determine the total amounts of the fatty tissue
osteodensitometry; laboratory testing included concentration of adiponectin in
ser...um utilising super-sensitive sandwich ELISA-method, insulin level measured
by RIA-method, glycemia OGTT-test, lipid parameters (HOL, HDL, LDL,
triglycerides) and C-reactive protein, gained by standard routine biochemical
protocols. All of the examinees were subjected to electrocardiogram and ehocardiogram
measurement, the analysis of graphs-coronary graphically findings
and calculation of atherogenic and HOMA-index.
Results: The level of adiponectin showed statisticaly significant negative
correllation with the key parameters of metabolic syndrome (obesity, hypertension,
hyperglycemia, dyslipidemia and insulin resistance), as well as coronary artery
disease. More accurately, the level of adiponectin is decreasing exact number of
coronary arteries disease and simptomatology progression. Plasma levels of
adiponectin positively correlated with ejection fraction, diastolic function and
HDL-cholesterol. Adiponectin may be a significant predictor of metabolic syndrome
and coronary heart disease, and an early representative marker of myocardial
ischemia and vascular inflammation, as well as hypoadiponectinaemia independent
cardiovascular risk factor.
Conclusion: This study, the first of its kind in Serbia and one of the few in
the world, will significantly contribute to acknowledgement of the role of
adiponectin as an early representative, diagnostic and predictive markers
in patients with metabolic syndrome and coronary artery disease.